Research
Neural
Patients can achieve significant weight reduction with the fixed-dose, extended-release combination of naltrexone and bupropion (NB-ER) compared with placebo when combined with a reduced-calorie diet and increased physical activity.
Practitioners should consider prescribing NB-ER for patients with obesity who are also engaging in dietary and physical activity changes.
StrongSupportsmedium confidence
Studies showing that patients can achieve significant weight reduction compared with placebo when treatment is combined with a reduced-calorie diet and increased physical activity.
Why this rating
Based on studies mentioned in the abstract.
Source
Appropriate use of the fixed-dose, extended-release combination of naltrexone and bupropion as treatment for obesity in primary care
Ethan Lazarus · Obesity Pillars · 2025
DOI 10.1016/j.obpill.2025.100170
reviewCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The unique combination of naltrexone and bupropion in NB-ER may work together to target POMC cells to prevent endogenous negative feedback, thereby decreasing appetite.Strong
- The appropriate use of NB-ER should consider the specific characteristics and adiposity-related complications of an individual.Strong
Related findings · Neural
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →